D. Boral Capital Reiterates Buy Rating for Compass Therapeutics (NASDAQ:CMPX)
Compass Therapeutics (NASDAQ:CMPX – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $32.00 price objective on the stock. A number of other equities research analysts have also issued reports on the company. Jefferies […]
Compass Therapeutics (NASDAQ:CMPX – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $32.00 price objective on the stock. A number of other equities research analysts have also issued reports on the company. Jefferies […]